Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
hepatocellular_carcinoma [2020/03/03 20:39] – [Related work] adminhepatocellular_carcinoma [2020/03/18 18:45] – [Related work] admin
Line 73: Line 73:
   - Subramaniam, Somasundaram, Robin K. Kelley, and Alan P. Venook. "A review of hepatocellular carcinoma (HCC) staging systems." [[http://cco.amegroups.com/article/view/2528/3943|Chinese clinical oncology]] 2.4 (2013).​​​   - Subramaniam, Somasundaram, Robin K. Kelley, and Alan P. Venook. "A review of hepatocellular carcinoma (HCC) staging systems." [[http://cco.amegroups.com/article/view/2528/3943|Chinese clinical oncology]] 2.4 (2013).​​​
   - Alexandrov, Ludmil B., et al. "The repertoire of mutational signatures in human cancer." [[https://www.nature.com/articles/s41586-020-1943-3#Sec17|Nature]] 578.7793 (2020): 94-101. \\  Analyzed WGS and WXS data of thousands of tumors available from TCGA and PCAWG consortia.   - Alexandrov, Ludmil B., et al. "The repertoire of mutational signatures in human cancer." [[https://www.nature.com/articles/s41586-020-1943-3#Sec17|Nature]] 578.7793 (2020): 94-101. \\  Analyzed WGS and WXS data of thousands of tumors available from TCGA and PCAWG consortia.
- +  - Dr. Sukeshi Arora's {{:sukeshi_arora_hcc_update_3.18.20.pptx|slides}}  presented in the HCC meeting on 2020-04-18, which summarizes statistics on the prognosis, the current clinical practice, and response to different treatments.
-----+